Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients

By A. Khorana, C. Francis, E. Culakova, N. Kuderer, G. Lyman. Cancer, 2008

779 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. (2013, background): “Most patients have additional risk factors, including comorbid conditions such as infection, immobility, or advanced age.(14) The benefit of prophylaxis increases with the risk of VTE.”
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. (2021, background): “Furthermore, VTE risk is especially high among certain subgroups, such as hospitalized patients, those undergoing systemic cancer therapy, and those with metastatic disease.(29-32) Other factors that have been associated with an increased risk for VTE include advanced age, male gender, and cancer-re”
Epidemiology of cancer-associated venous thrombosis. (2013, background): “1 000 000 cancer patients were followed for venous thrombosis.(18) Variables associated with venous thrombosis in a clinically significant way were ethnicity and the presence of comorbidities.”